Relationship between HLA class i antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas

Cancer Immunology, Immunotherapy

Volumn 59, Issue 3, 2010, Pages 465-472

  Cathro, Helen P ^a   Smolkin, Mark E ^a   Theodorescu, Dan ^a   Jo, Vickie Y ^a   Ferrone, Soldano ^b   Frierson Jr , Henry F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Antigen processing machinery; Bladder; HLA class I; Immune escape; Transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

BETA 2 MICROGLOBULIN; CALNEXIN; CALRETICULIN; FATTY ACID BINDING PROTEIN; HLA ANTIGEN CLASS 1; LOW MOLECULAR WEIGHT PROTEIN 10; LOW MOLECULAR WEIGHT PROTEIN 2; LOW MOLECULAR WEIGHT PROTEIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; OXIDOREDUCTASE; PROTEASOME; PROTEIN DELTA; PROTEIN ERP57; PROTEIN MB1; PROTEIN SUBUNIT; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MACHINE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; UROGENITAL TRACT TUMOR;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 73349138887     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0765-9     Document Type: Article

References (37)

1. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130 10.3322/canjclin.56.2.106 16514137
2. S Madersbacher W Hochreiter F Burkhard GN Thalmann H Danuser R Markwalder UE Studer 2003 Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy J Clin Oncol 21 690 696 10.1200/JCO.2003.05.101 12586807 (Pubitemid 46621904)
3. JP Stein G Lieskovsky R Cote S Groshen AC Feng S Boyd E Skinner, et al. 2001 Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 666 675 1:STN:280: DC%2BD3M7kvV2msQ%3D%3D 11157016
4. TH Totterman A Loskog M Essand 2005 The immunotherapy of prostate and bladder cancer BJU Int 96 728 735 10.1111/j.1464-410X.2005.05772.x 1:CAS:528:DC%2BD2MXhtFKnu7rN 16144528 (Pubitemid 41391419)
5. RL Ferris JL Hunt S Ferrone 2005 Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance Immunol Res 33 113 133 10.1385/IR:33:2:113 1:CAS:528:DC%2BD2MXht1Cls73M 16234579 (Pubitemid 41457464)
6. S Tamaki N Sanefuzi M Kawakami, et al. 2008 Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients Hum Immunol 69 88 93 10.1016/j.humimm.2008.01.010 1:CAS:528: DC%2BD1cXjs1Sqt74%3D 18361932
7. AJCC Cancer Staging Manual, American Joint Commission Cancer (2006) Springer, New York
8. X Wang M Campoli HS Cho T Ogino N Bandoh J Shen SY Hur, et al. 2005 A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections J Immunol Methods 299 139 151 10.1016/j.jim.2005.02.006 1:CAS:528:DC%2BD2MXks1aquro%3D 15896802 (Pubitemid 40725931)
9. N Bandoh T Ogino HS Cho SY Hur J Shen X Wang S Kato, et al. 2005 Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies Tissue Antigens 66 185 194 10.1111/j.1399-0039.2005.00462.x 1:CAS:528:DC%2BD2MXhtVyksr3M 16101829 (Pubitemid 41243306)
10. T Ogino N Bandoh T Hayashi N Miyokawa Y Harabuchi S Ferrone 2003 Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients Clin Cancer Res 9 4043 4051 1:CAS:528:DC%2BD3sXns1Ojt7c%3D 14519625
11. NJ Stam H Spits HL Ploegh 1986 Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products J Immunol 137 2299 2306 1:CAS:528: DyaL28XlslShs78%3D 3760563
12. F Grumet D Charron B Fendly R Levy D Ness 1980 HLA-DR epitope region definition by use of monoclonal antibody probes J Immunol 125 2785 2789 1:STN:280:DyaL3M%2FkvVSgtw%3D%3D 6159421
13. LA Lampson CA Fisher JP Whelan 1983 Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines J Immunol 130 2471 2478 1:CAS:528:DyaL3sXhvFKis7c%3D 6187860
14. W Wongsena G Sconocchia HS Cho CC Chang X Wang K Klumkrathok S Ferrone, et al. 2008 Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A Tissue Antigens 72 431 440 10.1111/j.1399-0039.2008.01118.x 1:CAS:528:DC%2BD1cXhsVCmsbbJ 18937790
15. T Ogino H Shigyo H Ishii, et al. 2006 HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker Cancer Res 66 9281 9289 10.1158/0008-5472.CAN-06-0488 1:CAS:528:DC%2BD28Xps1ahsrs%3D 16982773 (Pubitemid 44521150)
16. M Meissner TE Reichert M Kunkel W Gooding TL Whiteside S Ferrone B Seliger 2005 Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome Clin Cancer Res 11 2552 2560 10.1158/1078-0432.CCR-04-2146 1:CAS:528:DC%2BD2MXivFKisro%3D 15814633 (Pubitemid 40569453)
17. D Atkins S Ferrone GE Schmahl S Storkel B Seliger 2004 Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171 885 889 10.1097/01.ju.0000094807.95420.fe 1:CAS:528:DC%2BD2cXisV2ltQ%3D%3D 14713847 (Pubitemid 38090527)
18. M Vitale R Rezzani L Rodella G Zauli P Grigolato M Cadei DJ Hicklin, et al. 1998 HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions Cancer Res 58 737 742 1:CAS:528:DyaK1cXht1anurk%3D 9485029
19. M Vitale G Pelusi B Taroni G Gobbi C Micheloni R Rezzani F Donato, et al. 2005 HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage Clin Cancer Res 11 67 72 1:CAS:528: DC%2BD2MXhtVehur0%3D 15671529
20. T Kageshita S Hirai T Ono DJ Hicklin S Ferrone 1999 Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression Am J Pathol 154 745 754 1:STN:280:DyaK1M7otVOlsw%3D%3D 10079252
21. J Romero P Jimenez T Cabrera, et al. 2005 Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer Int J Cancer 113 605 610 10.1002/ijc.20499 1:CAS:528:DC%2BD2MXms1Gm 15455355 (Pubitemid 40038737)
22. D Atkins A Breuckmann GE Schmahl P Binner S Ferrone F Krummenauer S Storkel, et al. 2004 MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma Int J Cancer 109 265 273 10.1002/ijc.11681 1:CAS:528:DC%2BD2cXhvVCksrc%3D 14750179 (Pubitemid 38240930)
23. U Ritz F Momburg H Pilch C Huber MJ Maeurer B Seliger 2001 Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma Int J Oncol 19 1211 1220 1:CAS:528:DC%2BD3MXpt1Sktbg%3D 11713591
24. S Basu PK Srivastava 1999 Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity J Exp Med 189 797 802 10.1084/jem.189.5.797 1:CAS:528:DyaK1MXhsF2ju74%3D 10049943 (Pubitemid 29189684)
25. J Dissemond M Busch T Kothen J Mors TK Weimann A Lindeke M Goos, et al. 2004 Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma Cancer Lett 203 225 231 10.1016/j.canlet.2003.09.036 1:CAS:528:DC%2BD2cXjsV2rsw%3D%3D 14732231 (Pubitemid 38058690)
26. AM Mehta ES Jordanova GG Kenter S Ferrone GJ Fleuren 2008 Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma Cancer Immunol Immunother 57 197 206 10.1007/s00262-007-0362-8 1:CAS:528:DC%2BD2sXhtlaqt7vK 17622526 (Pubitemid 350159921)
27. B Seliger MJ Maeurer S Ferrone 2000 Antigen-processing machinery breakdown and tumor growth Immunol Today 21 455 464 10.1016/S0167-5699(00)01692- 3 1:CAS:528:DC%2BD3cXmtVCmsr0%3D 10953098 (Pubitemid 30693866)
28. LY Han MS Fletcher DL Urbauer P Mueller CN Landen AA Kamat YG Lin, et al. 2008 HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma Clin Cancer Res 14 3372 3379 10.1158/1078-0432.CCR-07-4433 1:CAS:528:DC%2BD1cXmslygsLc%3D 18519766
29. P Bassi GD Ferrante N Piazza R Spinadin R Carando G Pappagallo F Pagano 1999 Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort J Urol 161 1494 1497 10.1016/S0022-5347(05)68936-7 1:STN:280:DyaK1M3isFWjtw%3D%3D 10210380 (Pubitemid 29420803)
30. HW Herr 1997 Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome Br J Urol 80 762 765 1:STN:280: DyaK1c%2FlsFSjuw%3D%3D 9393299
31. F Saint JJ Patard B Groux Muscatelli MA Lefrere Belda Gil Diez S de Medina CC Abbou DK Chopin 2001 Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guerin treatment BJU Int 88 602 610 10.1046/j.1464-410X.2001.02394.x 1:CAS:528:DC%2BD3MXotVWlsLY%3D 11678759 (Pubitemid 34293806)
32. W Den Otter Z Dobrowolski A Bugajski B Papla AP Van Der Meijden JW Koten TA Boon, et al. 1998 Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients J Urol 159 1183 1186 10.1097/00005392-199804000-00021 (Pubitemid 28172790)
33. A Giannopoulos C Constantinides E Fokaeas C Stravodimos M Giannopoulou A Kyroudi A Gounaris 2003 The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence Clin Cancer Res 9 5550 5558 1:CAS:528:DC%2BD3sXpsVejtb8%3D 14654535
34. DB Glazier RR Bahnson DG McLeod RW von Roemeling EM Messing MS Ernstoff 1995 Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study J Urol 154 66 68 10.1016/S0022-5347(01)67228-8 1:STN:280:DyaK2M3psFWjsA%3D%3D 7776458
35. Y Luo X Chen TM Downs WC DeWolf MA O'Donnell 1999 IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy J Immunol 162 2399 2405 1:CAS:528:DyaK1MXhtVOktLo%3D 9973521
36. FG Perabo SC Muller 2004 Current and new strategies in immunotherapy for superficial bladder cancer Urology 64 409 421 10.1016/j.urology.2004.04.026 15351555 (Pubitemid 39200724)
37. GR Weiss MA O'Donnell K Loughlin K Zonno RJ Laliberte ML Sherman 2003 Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder J Immunother 26 343 348 10.1097/00002371-200307000- 00006 1:CAS:528:DC%2BD3sXmt1Omsr4%3D 12843796 (Pubitemid 36858718)